Journal of International Oncology

Journal of International Oncology››2019,Vol. 46››Issue (10): 613-616.doi:10.3760/cma.j.issn.1673-422X.2019.10.009

Previous ArticlesNext Articles

MYC inhibition associated mechanism research of Group3 medulloblastoma

Yang Xilin, Chen Xiaopin

  1. Department of Oncology, First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China

  • Online:2019-10-08Published:2019-12-20
  • Contact:Chen Xiaopin, Email: cxp640910@163.com E-mail:cxp640910@163.com

PDF

294

Abstract:Medulloblastoma (MB) is the most prevalent pediatric brain tumor. Group3 MB is the most malignant subgroup, quiet a part of which are MYC-amplified. Blocking the upstream gene sites of MYC is mainly achieved through the blockade of miR-494, DDX3, NOTCH1 pathway; BETi or ATR/Chk1 double-inhibition realizes the inhibition of duplication or transcription of MYC; as to the blockade of downstream genes of MYC, researchers mainly focus on LDHA, SETD8 and EZH2. All of these researches which target on MYC-amplified associated anti-tumor treatment mechanism present the theoretical basis for anti-MYC-associated medulloblastoma clinically.

Key words:Medulloblastoma,Genes, MYC,Group3,Treatment mechanism